TY - JOUR
T1 - Multiple myeloma
T2 - New staging systems for diagnosis, prognosis and response evaluation
AU - Rajkumar, S. Vincent
AU - Buadi, Francis
N1 - Funding Information:
Supported by Grants CA 107476, 62242, 100080, and 93842 from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
PY - 2007/12
Y1 - 2007/12
N2 - Multiple myeloma must be distinguished from monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and several other closely related plasma-cell disorders. In recent years, new systems have emerged for diagnosis, staging, and risk stratification of myeloma. The criteria recommended are primarily derived from the International Myeloma Working Group, with certain updates and clarifications. The International Staging System (ISS) is the standard for staging of myeloma. However, for therapeutic purposes, a risk-stratification model is used to define high-risk patients who can benefit from novel therapeutic strategies. The International Myeloma Working Group uniform response criteria have been developed as the standard for response assessment in current and future clinical trials. The criteria incorporate the category 'very good partial response' (VGPR) which, given its importance in predicting outcome following therapy, should be reported in all trials; such reporting will also enable better comparisons between therapies.
AB - Multiple myeloma must be distinguished from monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and several other closely related plasma-cell disorders. In recent years, new systems have emerged for diagnosis, staging, and risk stratification of myeloma. The criteria recommended are primarily derived from the International Myeloma Working Group, with certain updates and clarifications. The International Staging System (ISS) is the standard for staging of myeloma. However, for therapeutic purposes, a risk-stratification model is used to define high-risk patients who can benefit from novel therapeutic strategies. The International Myeloma Working Group uniform response criteria have been developed as the standard for response assessment in current and future clinical trials. The criteria incorporate the category 'very good partial response' (VGPR) which, given its importance in predicting outcome following therapy, should be reported in all trials; such reporting will also enable better comparisons between therapies.
KW - myeloma
KW - prognosis
KW - response criteria
KW - staging
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=36749092256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36749092256&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2007.10.002
DO - 10.1016/j.beha.2007.10.002
M3 - Review article
C2 - 18070712
AN - SCOPUS:36749092256
SN - 1521-6926
VL - 20
SP - 665
EP - 680
JO - Best Practice and Research in Clinical Haematology
JF - Best Practice and Research in Clinical Haematology
IS - 4
ER -